Drug Search Results
More Filters [+]

Enzastaurin

Alternative Names: enzastaurin, ly317615, DBI-102, DBI102, DBI 102, AR-101, AR101, DB102, enzastaurin hydrochloride
Latest Update: 2024-02-07
Latest Update Note: Clinical Trial Update

Product Description

A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin hydrochloride blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent. Also called LY317615. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/enzastaurin-hydrochloride)

Mechanisms of Action: PKC Beta Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Ehlers-Danlos Syndrome
Fast Track - Glioblastoma
Orphan Drug - Ehlers-Danlos Syndrome *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Enzastaurin

Countries in Clinic: Canada, China, El Salvador, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Diffuse Large B-Cell Lymphoma|Ehlers-Danlos Syndrome|Environmental Hypersensitivity|Glioblastoma|Peanut Hypersensitivity

Phase 2: Hyperpigmentation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial)

P3

Active, not recruiting

Ehlers-Danlos Syndrome

2025-08-30

DB102-01

P3

Active, not recruiting

Glioblastoma

2025-06-01

35%

PREVEnt

P3

Suspended

Ehlers-Danlos Syndrome

2025-06-01

72%

ARC008

P3

Completed

Peanut Hypersensitivity|Environmental Hypersensitivity

2023-04-27

70%

Recent News Events